Product Images Tadalafil

This is a table showing the effects of coadministered drugs with Tadalafil 20mg on blood pressure. The table includes Max Decrease in Standing/Sitting Blood Pressure over Placebo and Mean Differences.*

This is a chart listing co-administered drugs, including CYP3A inhibitors, inducers, antacids, and H2 antagonists, and their effects on AUC and Cmax levels in relation to Tadalafil. The chart recommends either dose adjustment or avoiding use altogether for certain drugs. There is also a fold change column indicating the change relative to Tadalafil alone.*

This is a table showing the effects of coadministered drugs on various substrates in the body. The substrates include CYP1A2, CYP2C9, CYP3A, P-glycoprotein, oral contraceptives, and NSAIDs. The effects are measured in terms of AUC and Cmax, and the fold change and 90%Cl recommendations are given. The table suggests that for most of the substrates, no dose adjustment is necessary when the drugs are coadministered.*

The text is a chart depicting the percentage of subjects without clinical worsening for Tadalafil 40 mg, Tadalafil 20 mg, and Placebo. It also shows the time to clinical worsening in days.*

This is a description for a prescription drug called Tadalafil. It is manufactured by Cipla and comes in a pack of 60 tablets. The text provides the NDC code 69097-526-03, and states that it is for prescription use only. There is also information on its expiration date, lot number, and a space for printing batch information.*

This is a description of Tadalafil Tablet, USP manufactured by Goa Ltd in India for Cipla USA, Inc. The tablet is available in 20mg dosage. The NDC number of the product is 63097-526-16. The text provides instructions on how to remove the tablet from the blister pack. The remaining text appears to be a mix of numbers, codes, and characters that are not easily understandable.*